Producers Of Innovative Drugs, Medical Devices Slated To Gain From China's Drive To Expand Hospitals, Insurance Coverage In 2011
This article was originally published in PharmAsia News
Executive Summary
BEIJING - Developers of innovative drugs and biopharmaceuticals, along with medical device makers, could all benefit as China's government steps up plans to expand health insurance coverage and rural medical facilities across the nation in 2011, according to a prominent analyst who monitors the Chinese healthcare system and reforms
You may also be interested in...
Facing Tougher Competition At Home, China's Mindray Should Target Global Mid- To High-end Market, Analysts Say
Facing a new round of marketing campaigns from international device makers targeting China's low- to mid-end hospital markets, Shenzhen based Mindray Medical will be better off focusing instead on mid- to high-end global markets to stay competitive, analysts say
Facing Tougher Competition At Home, China's Mindray Should Target Global Mid- To High-end Market, Analysts Say
Facing a new round of marketing campaigns from international device makers targeting China's low- to mid-end hospital markets, Shenzhen based Mindray Medical will be better off focusing instead on mid- to high-end global markets to stay competitive, analysts say
Are Chinese Price Cut Fears Overstated? Volume Likely To Drive Pharma Industry Growth, Analysts Say
SHANGHAI - As China gets closer to completing its initial $124 billion healthcare reforms next year, analysts are expecting a strong surge in volume-driven growth backed by more provincial drug reimbursement. A top priority of the Chinese reforms is to extend healthcare insurance to 90 percent (1.3 billion) of China's population by the end of 2011, a goal most expect the government to reach